Secondary Peritonitis Treatments

Find Secondary Peritonitis Treatments

Generic Name

Clindamycin

Brand Names

Tretinoin, Renova, Cleocin, Clindesse, ZIANA, Altreno, Clindagel, Atralin, Clindamycin Phoaphate, Tri-Luma, Clindacin, Twyneo, Xaciato, Retin-A, ClindaCare, Clindacin ETZ, Onexton, Neuac, Acanya

FDA approval date: May 22, 1970

Classification: Lincosamide Antibacterial

Form: Solution, Lotion, Injection, Suppository, Cream, Aerosol, Kit, Granule, Powder, Swab, Capsule, Gel

What is Tretinoin (Clindamycin)?

TWYNEO is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. TWYNEO is a combination tretinoin, a retinoid, and benzoyl peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Drug, Other

Study Phase: Phase 2

Summary: The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EG...

Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) With Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib

Enrollment Status: Recruiting

Publish Date: April 03, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myeloma (MM), in patients considered refractory to proteasome inhibitors (PIs). Multiple myeloma is an incurable clonal plasma cell disorder that comprises 10% o...

View All Clinical Trials